Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease-Reference-Cited by-同舟云学术

Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease

Published:2023-08-26 Issue:6 Volume:58 Page:636-637
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Jeffrey Angus W.¹^ORCID,Adams Leon A.¹²^ORCID

Affiliation:

1. Department of Hepatology Sir Charles Gairdner Hospital Nedlands Western Australia Australia

2. Medical School University of Western Australia Nedlands Western Australia Australia

Abstract

LINKED CONTENTThis article is linked to Zhan et al papers. To view these articles, visit https://doi.org/10.1111/apt.17635 and https://doi.org/10.1111/apt.17660

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17651

Reference8 articles.

1. Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis

2. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation

3. AutoFibroNet: A deep learning and multi‐photon microscopy‐derived automated network for liver fibrosis quantification in MAFLD

4. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease–Authors' reply;Alimentary Pharmacology & Therapeutics;2023-08-26